Other languages Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-20 EDT			5-day change	1st Jan Change
1.96 ^USD	+1.03%		-10.91%	-52.71%

05-14	HC Wainwright Adjusts Price Target on Leap Therapeutics to $5.50 From $7, Maintains Buy Rating	MT
05-13	Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13
Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration	03-18
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-18
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium	01-16
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients	01-02
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13
Top Premarket Decliners	23-10-16
Top Premarket Decliners	23-10-09
Leap Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients	23-07-12
Leap Therapeutics to Effect 10-for-1 Reverse Stock Split	23-06-20
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting	23-05-25
Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Leap Therapeutics Completes Enrollment of Part A of Phase 2 Study of Potential Colorectal Cancer Combination Therapy	23-04-12
Leap Therapeutics, Inc. Announces Completion of Enrollment in Part A of the Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients	23-04-12
Leap Therapeutics, Inc. Announces the Promotion of Jason Baum to Chief Scientific Officer, Effective April 1, 2023	23-03-24
Leap Therapeutics, Inc. Provides Update on Beigene Option Agreement for DKN-01	23-03-16
Tesla's China sales slow as price-cut boost wanes	23-02-28
Leap Therapeutics Acquires Flame Biosciences in All-Stock Deal	23-01-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Other languages

Filters